Fast track ā ArticlesNon-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study
Introduction
The incidence of oesophageal adenocarcinoma has risen substantially in the USA, western Europe, Australia, and in other developed countries over the past 30 years, with little sign of abating.1, 2 Incidence is highest in white men, and is about eight times greater than that for white women and five times greater than that for black men, although substantial increases have been recorded for every group.2, 3, 4 In the USA, oesophageal adenocarcinoma became the most common histological type of oesophageal cancer in the late 1990s. Although the cause of oesophageal adenocarcinoma and the underlying reasons for the rapid increase in incidence are not understood fully, the rise in obesity in many developed countries is thought to have a substantial role.5 Mortality remains high for those diagnosed with oesophageal adenocarcinoma, and most survive for less than 1 year after diagnosis.6
Most oesophageal adenocarcinomas arise in a specialised intestinal metaplastic epithelium as a result of goblet-cell metaplasia, a disorder called Barrett's oesophagus, which develops in about 10% of people with chronic gastro-oesophageal reflux disease.7, 8, 9 Every year, about 0Ā·5ā1Ā·0% of individuals with Barrett's oesophagus develop oesophageal adenocarcinoma; aneuploidy, tetraploidy, and loss of heterozygosity at chromosome 17p, with or without high-grade dysplasia, identify those at particularly high risk.9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 However, little is known about why in some people the oesophageal epithelium undergoes malignant transformation, whereas in others it remains in a fairly benign state indefinitely.25
Observational studies26, 27, 28 in human beings and mechanistic studies in animals27 suggest that aspirin and other non-steroidal anti-inflammatory drugs (NSAID) prevent development of colorectal cancer and premalignant adenomatous polyps. Clinical trials29, 30, 31, 32 of aspirin for prevention of recurrent adenomas or colon cancer generally support this notion, although findings have been inconsistent. By contrast, the role of NSAID in lowering the risk of oesophageal cancer risk has not been addressed thoroughly, although several studies of human beings33, 34, 35, 36, 37 and animals38, 39 suggest a protective effect. An inexpensive, widely available, and fairly safe means of preventing neoplastic progression in people at high risk of oesophageal cancer would have substantial benefits in terms of public health and economics.40, 41, 42, 43
We aimed to assess the role of NSAID in the development of oesophageal adenocarcinoma and precursor lesions in a cohort of people with Barrett's oesophagus. By use of prospective, longitudinal observational data, we analysed the association between NSAID intake and incidence of oesophageal adenocarcinoma, aneuploidy, and tetraploidy.
Section snippets
Study participants
We analysed participants in the Seattle Barrett's oesophagus projectāa dynamic cohort study that began in 1983. Every participant in this continuing programme of cancer surveillance has periodic endoscopy and multiple biopsies at every endoscopy according to a standard protocol.24, 44 From February, 1995, the study was expanded to include an extensive personal interview about medical history, diet, history of use of certain prescription and over-the-counter drugs, and anthropometric
Results
350 people were eligible for analyses. Of these, 105 (30%) were ongoing participants who had been under surveillance for a median of 62Ā·4 months (range 2Ā·4ā148Ā·8), and 245 (70%) were newly diagnosed with Barrett's oesophagus at baseline. The median number of follow-up visits was five (1ā20) for 61 (17%) people with high-grade dysplasia at baseline, with a median time between visits of 6Ā·0 months (0Ā·7ā32Ā·2), and three visits (1ā15) for those without high-grade dysplasia at baseline, with a
Discussion
We have shown that people who took aspirin or other NSAID regularly had a substantially lower incidence of oesophageal adenocarcinoma, aneuploidy, and to a lesser extent, tetraploidy, compared with those who did not take such drugs regularly. These findings persisted after adjustment for major risk factors for oesophageal adenocarcinoma, including age, sex, education, cigarette use, ratio of waist to hip, and body-mass index. We found that risk did not vary with these factors. Furthermore, risk
Glossary
- Aneuploidy
- A population of cells with abnormal DNA content, separated from the diploid peak, and representing more than 2Ā·5% of cells.
- Tetraploidy
- A population of cells increased beyond the normal level present during stage G2 of the cell cycle (>6%) and with DNA content between 3Ā·85 and 4Ā·10N inclusive.
References (53)
Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American College of Gastroenterology
Am J Gastroenterol
(1998)- et al.
Barrett's esophagus: development of dysplasia and adenocarcinoma
Gastroenterology
(1989) - et al.
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's esophagus registry
Am J Gastroenterol
(1999) - et al.
Adenocarcinoma and Barrett's esophagus. An overrated risk?
Gastroenterology
(1984) - et al.
Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma
Am J Gastroenterol
(1999) - et al.
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression
Am J Gastroenterol
(2001) - et al.
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables
Am J Gastroenterol
(2001) - et al.
NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action
Am J Gastroenterol
(2002) - et al.
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis
Gastroenterology
(2003) - et al.
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus
Gastroenterology
(2002)
NSAIDs and esophageal cancer: ready for trials but not yet broad clinical application
Gastroenterology
Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk
Am J Gastroenterol
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets
Am J Gastroenterol
Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort
Gastroenterology
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
Am J Gastroenterol
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males
Cancer
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973ā1995
Int J Cancer
Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States
Am J Gastroenterol
Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States
Cancer
Population attributable risks of esophageal and gastric cancers
J Natl Cancer Inst
Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas
Int J Cancer
Barrett's esophagus. Natural history, incidence, etiology, and complications
Gastroenterol Clin North Am
Barrett's esophagus: update on screening, surveillance, and treatment
Arch Intern Med
Are screening and surveillance for Barrett's oesophagus really worthwhile?
Gut
The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus
N Engl J Med
The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4Ā·8 years
Am J Gastroenterol
Cited by (191)
Effect of nonsteroidal anti-inflammatory drugs on Barrett's esophagus risk: a systematic review and meta-analysis
2021, Clinics and Research in Hepatology and GastroenterologyCurrent Status of Chemoprevention in Barrett's Esophagus
2021, Gastrointestinal Endoscopy Clinics of North AmericaCitation Excerpt :In contrast, an analysis of data from studies in BEACON76 (involving 1474 BE cases and 2256 population-based controls) found no association between use of any NSAIDs and the risk of BE (OR, 1.00; 95% CI, 0.76ā1.32). Therefore, it is likely that the most, if not all, of the protective effect of NSAIDs on risk of EA occurs after the development of BE.77 Analogous to colon cancer and polyps, NSAIDs may stop progression from BE to EAC,77 but not the development of BE.
Lifestyle and Cancer Prevention
2019, Abeloffās Clinical OncologyEpidemiology, Risk Factors, and Clinical Manifestations of Esophageal Cancer
2019, Shackelford's Surgery of the Alimentary Tract: 2 Volume SetMaintenance proton pump inhibition therapy and risk of oesophageal cancer
2018, Cancer Epidemiology